Show your working: launch revenue is the lagging indicator, and this season proves it
Headline growth rates from small launches are easy to produce and hard to compare. The results that persuade pair revenue with evidence of demand and a plan the economics can fund.
Percentages without denominators
Read this week's third-quarter releases in a row and the growth rates blur together. Kura Oncology's KOMZIFTI grew 53% sequentially to $13.9 million. Tonix's TONMYA reached approximately $15 million, up 37% on the second quarter. Autolus reported AUCATZYL revenue of $41.2 million, up 95% year-over-year. Delcath's total revenue rose to $35.1 million from $20.6 million a year earlier. All of these are strong figures, but they use different comparison periods and different starting bases, and none of them says much on its own.
CompePharma's position is that revenue is the lagging indicator of a launch. It tells you what happened last quarter. What it can't tell you is whether the next quarter will look the same. The companies that make the best case this season are the ones that show their working.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Reimbursement, not approval, is the commercial gate, and leaders should plan accordingly
This month's payer decisions from CMS, China's NRDL and Medicare show that price and access are set by policy calendars. Companies that treat them as afterthoughts will pay for it.
Gross margin is the number that turns a launch into a business
Revenue growth was easy to find in this earnings season. The companies that pair it with unit economics, as Delcath and Autolus have begun to, are the ones that will set their own terms.
The first launch is a down payment: this earnings season rewards the label that funds the next one
Kura, Autolus, ADC Therapeutics and others are using first-product revenue to underwrite a second act. The risk is trying to do both at once.